share_log

Adial Pharmaceuticals | S-3: Registration statement for specified transactions by certain issuers

Adial Pharmaceuticals | S-3: Registration statement for specified transactions by certain issuers

Adial Pharmaceuticals | S-3：特定交易注册声明
美股SEC公告 ·  04/12 16:28

Moomoo AI 已提取核心信息

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on April 12, 2024, for a Form S-3 registration statement under the Securities Act of 1933. This filing pertains to the resale of up to 2,369,000 shares of common stock by Selling Stockholders, which includes shares issuable upon the exercise of Series C Common Warrants and Placement Agent Warrants. The Selling Stockholders include certain investors and designees of H.C. Wainwright & Co., LLC, the placement agent in connection with a private placement transaction that closed on March 6, 2024. The registration of these shares does not necessarily mean that the Selling Stockholders will sell their shares, nor does it guarantee that any proceeds from the sale will be received by Adial Pharmaceuticals. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'ADIL'. The filing of this registration statement is part of Adial Pharmaceuticals' contractual obligations to provide for the resale by the Selling Stockholders of the shares of common stock offered.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on April 12, 2024, for a Form S-3 registration statement under the Securities Act of 1933. This filing pertains to the resale of up to 2,369,000 shares of common stock by Selling Stockholders, which includes shares issuable upon the exercise of Series C Common Warrants and Placement Agent Warrants. The Selling Stockholders include certain investors and designees of H.C. Wainwright & Co., LLC, the placement agent in connection with a private placement transaction that closed on March 6, 2024. The registration of these shares does not necessarily mean that the Selling Stockholders will sell their shares, nor does it guarantee that any proceeds from the sale will be received by Adial Pharmaceuticals. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'ADIL'. The filing of this registration statement is part of Adial Pharmaceuticals' contractual obligations to provide for the resale by the Selling Stockholders of the shares of common stock offered.
临床阶段的生物制药公司Adial Pharmaceuticals, Inc. 已于2024年4月12日向美国证券交易委员会（SEC）提交了根据1933年《证券法》提交了S-3表格注册声明的注册声明。该文件涉及卖方股东转售最多2369,000股普通股，其中包括行使C系列普通认股权证和配售代理认股权证时可发行的股票。出售股东包括H.C. Wainwright & Co., LLC的某些投资者和指定人。H.C. Wainwright & Co., LLC是与2024年3月6日完成的私募交易相关的配售代理人。这些股票的注册并不一定意味着卖出股东将出售其股份，也不保证Adial Pharmicals会收到任何出售收益。该公司的普通股在纳斯达克资本市场上市，股票代码为 “ADIL”。本注册声明的提交是Adial Pharmaceuticals合同义务的一部分，该义务要求卖出股东转售所发行的普通股。
临床阶段的生物制药公司Adial Pharmaceuticals, Inc. 已于2024年4月12日向美国证券交易委员会（SEC）提交了根据1933年《证券法》提交了S-3表格注册声明的注册声明。该文件涉及卖方股东转售最多2369,000股普通股，其中包括行使C系列普通认股权证和配售代理认股权证时可发行的股票。出售股东包括H.C. Wainwright & Co., LLC的某些投资者和指定人。H.C. Wainwright & Co., LLC是与2024年3月6日完成的私募交易相关的配售代理人。这些股票的注册并不一定意味着卖出股东将出售其股份，也不保证Adial Pharmicals会收到任何出售收益。该公司的普通股在纳斯达克资本市场上市，股票代码为 “ADIL”。本注册声明的提交是Adial Pharmaceuticals合同义务的一部分，该义务要求卖出股东转售所发行的普通股。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间